RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreatic CancerPancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Interventions
DRUG

RP72

RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.

DRUG

Gemcitabine

Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.

Trial Locations (2)

Unknown

RECRUITING

Chi Mei Hospital, Liouying, Tainan City

RECRUITING

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

T-TOP Clinical Research Co., Ltd.

INDUSTRY

lead

Rise Biopharmaceuticals, Inc.

INDUSTRY

NCT04338763 - RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter